5.28
전일 마감가:
$5.10
열려 있는:
$5.22
하루 거래량:
3.02M
Relative Volume:
0.70
시가총액:
$823.18M
수익:
$2.80M
순이익/손실:
$-115.18M
주가수익비율:
-6.2316
EPS:
-0.8473
순현금흐름:
$-94.03M
1주 성능:
+14.04%
1개월 성능:
+34.01%
6개월 성능:
+70.87%
1년 성능:
+98.50%
Absci Corp Stock (ABSI) Company Profile
명칭
Absci Corp
전화
(360) 949-1041
주소
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ABSI
Absci Corp
|
5.28 | 795.12M | 2.80M | -115.18M | -94.03M | -0.8473 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-02 | 개시 | JP Morgan | Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-01-22 | 개시 | Needham | Buy |
| 2024-10-02 | 개시 | Guggenheim | Buy |
| 2024-07-03 | 개시 | Morgan Stanley | Overweight |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | 개시 | H.C. Wainwright | Buy |
| 2022-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2022-07-18 | 개시 | Truist | Buy |
| 2022-03-02 | 재개 | Cowen | Market Perform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-11-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-08-16 | 개시 | BofA Securities | Neutral |
| 2021-08-16 | 개시 | Cowen | Market Perform |
| 2021-08-16 | 개시 | Credit Suisse | Outperform |
| 2021-08-16 | 개시 | Stifel | Hold |
모두보기
Absci Corp 주식(ABSI)의 최신 뉴스
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? - AOL.com
The 1 AI Stock I'd Put in a Time Capsule and Open in 2036 - AOL.com
The 1 AI stock I'd put in a time capsule and open in 2036 - MSN
Grail's Slump Enters Week 10. Is There Any End in Sight? - AOL.com
Doximity Stock Just Got Crushed. Is This a Rare Chance to Buy a High-Quality Growth Company on Sale? - AOL.com
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
2 Stocks That Could Realistically Double by 2030 - AOL.com
ABSI Price Today: Absci Corporation Stock Price, Quote & Chart | MEXC - MEXC Exchange
Absci Insider Buyers Pleased With US$700k Return On Investment - Yahoo Finance
AI-driven drug developer Absci lines up Jefferies and Goldman talks - Stock Titan
Portland InnoAbsci's move into generative AI | Why former Hydro Flask CEO joined Puffin - The Business Journals
Morgan Stanley Trims Price Target on Absci to $4.10 From $4.20, Keeps Equalweight Rating - Moomoo
AMD Reveals A $6.5 Million Marvell Bet That's Already Soaring - Sahm
Insider Buying: Menelas Pangalos Acquires Shares in Absci Corp (ABSI) - GuruFocus
Absci Corp (ABSI) director Menelas Pangalos adds 37,453 shares in open-market buy - Stock Titan
AMD Reveals A $6.5 Million Marvell Bet That's Already Soaring - Benzinga
HC Wainwright Has Optimistic Outlook of Absci Q3 Earnings - MarketBeat
Absci price target raised to $11 from $9 at JonesResearch - TipRanks
TradingKey - TradingKey
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $11 - 富途牛牛
Earnings call transcript: Absci Corp misses revenue forecast in Q1 2026 - Investing.com UK
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Absci Corporation (ABSI) reports Q1 loss, misses revenue estimates - MSN
Absci Corp. Charts High-Stakes Path With ABS-201 - TipRanks
Needham Reiterates Buy Rating on ABSI with Price Target of $7.00 - GuruFocus
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Absci (NASDAQ:ABSI) Given New $11.00 Price Target at Truist Financial - MarketBeat
Absci’s ABS-201 Hair-Loss Trial Moves Forward: What Early-Stage Data Could Mean for ABSI - TipRanks
Absci (NASDAQ:ABSI) Shares Gap DownShould You Sell? - MarketBeat
Absci Shares Fall After 1Q Loss Widens - Moomoo
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $11 - 富途牛牛
Absci Corporation (NASDAQ:ABSI) Q1 2026 Earnings Call Transcript - Insider Monkey
12 Health Care Stocks Moving In Friday's Pre-Market SessionAbsci (NASDAQ:ABSI), Amylyx Pharmaceuticals - Benzinga
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results - The Manila Times
TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛
Absci (NASDAQ:ABSI) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
Absci reports Q1 EPS (19c), consensus (20c) - TipRanks
Earnings call transcript: Absci’s Q1 2026 revenue falls short, stock dips - Investing.com Nigeria
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Absci’s Q1 2026 revenue falls short, stock dips By Investing.com - Investing.com South Africa
Absci Corp (NASDAQ:ABSI) Plunges on 86% Q1 Revenue Miss Despite Clinical Advances - ChartMill
Absci Q1 Earnings Call Highlights - Yahoo Finance
Hair-loss drug trial reaches patient dosing; Absci adds ABS-202 - Stock Titan
Absci (ABSI) posts Q1 2026 results, advances ABS-201 and adds ABS-202 - Stock Titan
Absci (NASDAQ: ABSI) Q1 loss widens as revenue falls to $0.2M - Stock Titan
Absci : Corporate Presentation, May 2026 - marketscreener.com
Absci (ABSI) Q1 2026 Earnings Call Transcript - The Globe and Mail
Absci Corp (ABSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):